At ASCO and EAU 2025, Professor Shouzhen Chen (Qilu Hospital, Shandong University) shared an in-depth overview of molecular subtyping in mCRPC. He emphasized established targets like HRR and MSI-H, explored the promise of combining PARP inhibitors with radionuclides, and highlighted emerging biomarkers such as B7-H3. His message: precision therapy is rapidly evolving, but challenges in biomarker interpretation and treatment stratification remain.
